5-fluorouracil improves mortality in stage III colorectal cancer patients.
In this study, researchers from San Diego, California, assessed the survival influence of 5-fluorouracil in patients with microsatellite instability-high tumors.
The research team evaluated 204 consecutive stage II and III colorectal cancer patients between 1982 and 1999.
They extracted archival DNA, and assessed microsatellite instability using National Cancer Institute-recommended markers.
The researchers identified 36 microsatellite instability-high and 168 non-microsatellite instability-high tumors.
|Microsatellite instability-high tumors were associated with proximal colon location.|
They determined that microsatellite instability-high tumors were associated with proximal colon location, presence of mucin, and surrounding lymphoid reaction.
There was no difference identified between microsatellite instability-high and non-microsatellite instability-high groups. However, the benefit of 5-fluorouracil differed between these groups.
The team found that patients with non-microsatellite instability-high tumors who received 5-fluorouracil had better survival.
Dr John Carethers's team concluded, "There is improved survival in patients with non-microsatellite instability-high tumors after 5-fluorouracil-based chemotherapy".
"The microsatellite instability status of a patient’s colorectal cancer may indicate differences in 5-fluorouracil-based chemosensitivity".